Headline: AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Location: Ocala, FL, US
Post Date: Apr 18, 2024 8:45 AM
TAG ID: pznews557513
DocID: 9091678
Word Count: approx. 162 words
Full story:
AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need. The CEO Corner segment is now available here.  About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Investor Contact:


Jenene Thomas

(833) 475-8247

[email protected]

Please login to download this Story